Patients with type 1 diabetes and albuminuria have a reduced brain glycolytic capability that is correlated with brain atrophy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Patients with type 1 diabetes and albuminuria have a reduced brain glycolytic capability that is correlated with brain atrophy. / Vestergaard, Mark B.; Laursen, Jens Christian; Heinrich, Niels Søndergaard; Rossing, Peter; Hansen, Tine Willum; Larsson, Henrik B. W.

I: Frontiers in Neuroscience, Bind 17, 1229509, 2023.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Vestergaard, MB, Laursen, JC, Heinrich, NS, Rossing, P, Hansen, TW & Larsson, HBW 2023, 'Patients with type 1 diabetes and albuminuria have a reduced brain glycolytic capability that is correlated with brain atrophy', Frontiers in Neuroscience, bind 17, 1229509. https://doi.org/10.3389/fnins.2023.1229509

APA

Vestergaard, M. B., Laursen, J. C., Heinrich, N. S., Rossing, P., Hansen, T. W., & Larsson, H. B. W. (2023). Patients with type 1 diabetes and albuminuria have a reduced brain glycolytic capability that is correlated with brain atrophy. Frontiers in Neuroscience, 17, [1229509]. https://doi.org/10.3389/fnins.2023.1229509

Vancouver

Vestergaard MB, Laursen JC, Heinrich NS, Rossing P, Hansen TW, Larsson HBW. Patients with type 1 diabetes and albuminuria have a reduced brain glycolytic capability that is correlated with brain atrophy. Frontiers in Neuroscience. 2023;17. 1229509. https://doi.org/10.3389/fnins.2023.1229509

Author

Vestergaard, Mark B. ; Laursen, Jens Christian ; Heinrich, Niels Søndergaard ; Rossing, Peter ; Hansen, Tine Willum ; Larsson, Henrik B. W. / Patients with type 1 diabetes and albuminuria have a reduced brain glycolytic capability that is correlated with brain atrophy. I: Frontiers in Neuroscience. 2023 ; Bind 17.

Bibtex

@article{2984059196484507a251c5ba5311c0cb,
title = "Patients with type 1 diabetes and albuminuria have a reduced brain glycolytic capability that is correlated with brain atrophy",
abstract = "INTRODUCTION: Patients with type 1 diabetes (T1D) demonstrate brain alterations, including white matter lesions and cerebral atrophy. In this case-control study, we investigated if a reason for this atrophy could be because of diabetes-related complications affecting cerebrovascular or cerebral glycolytic functions. Cerebral physiological dysfunction can lead to energy deficiencies and, consequently, neurodegeneration.METHODS: We examined 33 patients with T1D [18 females, mean age: 50.8 years (range: 26-72)] and 19 matched healthy controls [7 females, mean age: 45.0 years (range: 24-64)]. Eleven (33%) of the patients had albuminuria. Total brain volume, brain parenchymal fraction, gray matter volume and white matter volume were measured by anatomical MRI. Cerebral vascular and glycolytic functions were investigated by measuring global cerebral blood flow (CBF), cerebral metabolic rate of oxygen (CMRO 2) and cerebral lactate concentration in response to the inhalation of hypoxic air (12-14% fractional oxygen) using phase-contrast MRI and magnetic resonance spectroscopy (MRS) techniques. The inspiration of hypoxic air challenges both cerebrovascular and cerebral glycolytic physiology, and an impaired response will reveal a physiologic dysfunction. RESULTS: Patients with T1D and albuminuria had lower total brain volume, brain parenchymal fraction, and gray matter volume than healthy controls and patients without albuminuria. The inhalation of hypoxic air increased CBF and lactate in all groups. Patients with albuminuria had a significantly ( p  = 0.032) lower lactate response compared to healthy controls. The CBF response was lower in patients with albuminuria compared to healthy controls, however not significantly ( p  = 0.24) different. CMRO 2 was unaffected by the hypoxic challenge in all groups ( p  > 0.16). A low lactate response was associated with brain atrophy, characterized by reduced total brain volume ( p  = 0.003) and reduced gray matter volume ( p  = 0.013). DISCUSSION: We observed a reduced response of the lactate concentration as an indication of impaired glycolytic activity, which correlated with brain atrophy. Inadequacies in upregulating cerebral glycolytic activity, perhaps from reduced glucose transporters in the brain or hypoxia-inducible factor 1 pathway dysfunction, could be a complication in diabetes contributing to the development of neurodegeneration and declining brain health.",
author = "Vestergaard, {Mark B.} and Laursen, {Jens Christian} and Heinrich, {Niels S{\o}ndergaard} and Peter Rossing and Hansen, {Tine Willum} and Larsson, {Henrik B. W.}",
note = "Copyright {\textcopyright} 2023 Vestergaard, Laursen, Heinrich, Rossing, Hansen and Larsson.",
year = "2023",
doi = "10.3389/fnins.2023.1229509",
language = "English",
volume = "17",
journal = "Frontiers in Neuroscience",
issn = "1662-4548",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Patients with type 1 diabetes and albuminuria have a reduced brain glycolytic capability that is correlated with brain atrophy

AU - Vestergaard, Mark B.

AU - Laursen, Jens Christian

AU - Heinrich, Niels Søndergaard

AU - Rossing, Peter

AU - Hansen, Tine Willum

AU - Larsson, Henrik B. W.

N1 - Copyright © 2023 Vestergaard, Laursen, Heinrich, Rossing, Hansen and Larsson.

PY - 2023

Y1 - 2023

N2 - INTRODUCTION: Patients with type 1 diabetes (T1D) demonstrate brain alterations, including white matter lesions and cerebral atrophy. In this case-control study, we investigated if a reason for this atrophy could be because of diabetes-related complications affecting cerebrovascular or cerebral glycolytic functions. Cerebral physiological dysfunction can lead to energy deficiencies and, consequently, neurodegeneration.METHODS: We examined 33 patients with T1D [18 females, mean age: 50.8 years (range: 26-72)] and 19 matched healthy controls [7 females, mean age: 45.0 years (range: 24-64)]. Eleven (33%) of the patients had albuminuria. Total brain volume, brain parenchymal fraction, gray matter volume and white matter volume were measured by anatomical MRI. Cerebral vascular and glycolytic functions were investigated by measuring global cerebral blood flow (CBF), cerebral metabolic rate of oxygen (CMRO 2) and cerebral lactate concentration in response to the inhalation of hypoxic air (12-14% fractional oxygen) using phase-contrast MRI and magnetic resonance spectroscopy (MRS) techniques. The inspiration of hypoxic air challenges both cerebrovascular and cerebral glycolytic physiology, and an impaired response will reveal a physiologic dysfunction. RESULTS: Patients with T1D and albuminuria had lower total brain volume, brain parenchymal fraction, and gray matter volume than healthy controls and patients without albuminuria. The inhalation of hypoxic air increased CBF and lactate in all groups. Patients with albuminuria had a significantly ( p  = 0.032) lower lactate response compared to healthy controls. The CBF response was lower in patients with albuminuria compared to healthy controls, however not significantly ( p  = 0.24) different. CMRO 2 was unaffected by the hypoxic challenge in all groups ( p  > 0.16). A low lactate response was associated with brain atrophy, characterized by reduced total brain volume ( p  = 0.003) and reduced gray matter volume ( p  = 0.013). DISCUSSION: We observed a reduced response of the lactate concentration as an indication of impaired glycolytic activity, which correlated with brain atrophy. Inadequacies in upregulating cerebral glycolytic activity, perhaps from reduced glucose transporters in the brain or hypoxia-inducible factor 1 pathway dysfunction, could be a complication in diabetes contributing to the development of neurodegeneration and declining brain health.

AB - INTRODUCTION: Patients with type 1 diabetes (T1D) demonstrate brain alterations, including white matter lesions and cerebral atrophy. In this case-control study, we investigated if a reason for this atrophy could be because of diabetes-related complications affecting cerebrovascular or cerebral glycolytic functions. Cerebral physiological dysfunction can lead to energy deficiencies and, consequently, neurodegeneration.METHODS: We examined 33 patients with T1D [18 females, mean age: 50.8 years (range: 26-72)] and 19 matched healthy controls [7 females, mean age: 45.0 years (range: 24-64)]. Eleven (33%) of the patients had albuminuria. Total brain volume, brain parenchymal fraction, gray matter volume and white matter volume were measured by anatomical MRI. Cerebral vascular and glycolytic functions were investigated by measuring global cerebral blood flow (CBF), cerebral metabolic rate of oxygen (CMRO 2) and cerebral lactate concentration in response to the inhalation of hypoxic air (12-14% fractional oxygen) using phase-contrast MRI and magnetic resonance spectroscopy (MRS) techniques. The inspiration of hypoxic air challenges both cerebrovascular and cerebral glycolytic physiology, and an impaired response will reveal a physiologic dysfunction. RESULTS: Patients with T1D and albuminuria had lower total brain volume, brain parenchymal fraction, and gray matter volume than healthy controls and patients without albuminuria. The inhalation of hypoxic air increased CBF and lactate in all groups. Patients with albuminuria had a significantly ( p  = 0.032) lower lactate response compared to healthy controls. The CBF response was lower in patients with albuminuria compared to healthy controls, however not significantly ( p  = 0.24) different. CMRO 2 was unaffected by the hypoxic challenge in all groups ( p  > 0.16). A low lactate response was associated with brain atrophy, characterized by reduced total brain volume ( p  = 0.003) and reduced gray matter volume ( p  = 0.013). DISCUSSION: We observed a reduced response of the lactate concentration as an indication of impaired glycolytic activity, which correlated with brain atrophy. Inadequacies in upregulating cerebral glycolytic activity, perhaps from reduced glucose transporters in the brain or hypoxia-inducible factor 1 pathway dysfunction, could be a complication in diabetes contributing to the development of neurodegeneration and declining brain health.

U2 - 10.3389/fnins.2023.1229509

DO - 10.3389/fnins.2023.1229509

M3 - Journal article

C2 - 37869511

VL - 17

JO - Frontiers in Neuroscience

JF - Frontiers in Neuroscience

SN - 1662-4548

M1 - 1229509

ER -

ID: 385015912